EF-031 | Solid Tumors Treatment

EF-031

Solid Tumors Treatment

Targeting intractable malignant brain tumors and pancreatic cancer:

Everfront Biotech Inc. has successfully developed EF-031, a novel therapeutic agent for the treatment of solid tumors. This drug is administered systemically in combination with the standard-of-care treatment. The efficacy was evaluated using two in vivo animal models with oral EF-API-001. The results demonstrated that EF-031 effectively inhibited the growth of PDAC tumors and significantly extended the survival of diseased animals.

Glioblastoma (GBM)

The most common and lethal primary brain tumor Glioblastoma (GBM) is highly resistant to conventional radiotherapy and chemotherapy and cannot be effectively controlled by surgical resection. As recurrence is inevitable and progresses rapidly, GBM is considered essentially incurable. Survival rate is low and median life expectancy is 6 months after relapse.
Glioblastoma (GBM) is the most common and lethal primary brain tumor that is highly resistant to conventional radiotherapy and chemotherapy, which cannot be effectively controlled by surgical resection. Recurrence is inevitable and progresses rapidly, rendering GBM essentially incurable. Survival rate is low, median is half a year after relapse.
A great challenge in current therapies lies in delivering chemotherapeutic agents effectively to the tumor location in the presence of blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), a hurdle that is reducing the efficacy of anti-tumor drugs in GBM therapy.

Pancreatic cancer (PC)

While the mortality rate of pancreatic cancer (PC) is rising rapidly, treating it remains a formidable challenge. Surgery followed by adjuvant chemotherapy is the standard of care but, without additional therapy, over 90% of patients relapse and die. PC remains highly resistant to conventional chemotherapy and only 5% of patients survive more than 5 years.

Our Innovative Approach

Use Small Molecules Drugs as Our Key Therapeutics

EF-API-001 has been extensively studied and identified as a key player in exerting significant pharmacological effects against various types of cancer. It exhibits multiple targeting capabilities, including anti-tumor stem cell properties, anti-migration and anti-invasion characteristics, and the ability to attenuate immunosuppression at the epigenetic level. By modulating DNA methyltransferase 1 (DNMT1) and inhibiting the mammalian target of rapamycin (mTOR), EF-API-001 reduces PD-L1 protein levels and suppresses Axl activation, respectively.

Harness the Power of the Human Immune System

We are actively identifying and developing active compounds that can enhance the body’s natural defense capabilities across multiple indicators. EF-API-001 has been extensively characterized and recognized as a potent active pharmaceutical ingredient capable of inhibiting CD44ICD (CD44 intracellular domain) signaling. By modulating the CD44ICD-PD-L1 axis, EF-API-001 holds the potential to reverse the immunosuppressive microenvironment.

Improving Efficacy with Targeted Drug Delivery

The small molecule active pharmaceutical ingredient EF-API-001 demonstrates high permeability and possesses the capability to cross the blood-brain barrier. Through strategic formulation design, it facilitates the targeted delivery of higher drug concentrations to specific therapeutic organs, such as the pancreas and the brain (cerebrum and cerebellum).

Product Profile

Product Name

EF-031

Disease

Solid tumor

Target Market

North America, Europe, Asia, China, Japan, others

Market Size

US market worth around USD 43.7 billion

Competition Size

For brain tumors, patents on much less effective Gliadel® wafer and TMZ have expired. For pancreatic cancer, animal study revealed much more survival than the chemotherapy drug, Gemcitabine.

Objective Size

The standard-of-care combination therapy targeting both chemotherapy and targeted therapy markets, aiming to secure a 15% market share through direct competition.